Genetic toxicology in silico protocol

Catrin Hasselgren(Gene Therapy Laboratory), Ernst Ahlberg(AstraZeneca (Sweden)), Yumi Akahori(Chemicals Evaluation and Research Institute), Alexander Amberg(Sanofi (Germany)), Lennart T. Anger(Sanofi (Germany)), Franck Atienzar(UCB Pharma (Belgium)), Scott S. Auerbach(National Institute of Environmental Health Sciences), Lisa Beilke, Phillip Bellion(DSM (Switzerland)), Romualdo Benigni, Joel P. Bercu(Gilead Sciences (United States)), Ewan D. Booth(Syngenta (United Kingdom)), Dave Bower(LeadScope (United States)), Alessandro Brigo(Roche (Switzerland)), Zoryana Cammerer(Janssen (United States)), M Cronin(Liverpool John Moores University), Ian Crooks(British American Tobacco (United Kingdom)), Kevin P. Cross(LeadScope (United States)), Laura Custer(Bristol-Myers Squibb (United States)), Krista L. Dobo(Pfizer (United States)), Tatyana Y. Doktorova(Nestlé (Switzerland)), David Faulkner(Lawrence Berkeley National Laboratory), Kevin A. Ford(LeadScope (United States)), Marie Fortin(Rutgers, The State University of New Jersey), Markus Frericks(Leuphana University of Lüneburg), Samantha Gad-McDonald(Leuphana University of Lüneburg), Nichola Gellatly(National Centre for the Replacement Refinement and Reduction of Animals in Research), Helga H.J. Gerets(Sanofi (Germany)), Véronique Gervais(Health Canada), Susanne Glowienke(AstraZeneca (United Kingdom)), Jacky Van Gompel(Leuphana University of Lüneburg), James Harvey(GlaxoSmithKline (United Kingdom)), Jedd Hillegass(AstraZeneca (United Kingdom)), Masamitsu Honma(National Institute of Health Sciences), Jui‐Hua Hsieh(Kelly Services (United States)), Chia-Wen Hsu(Leuphana University of Lüneburg), Tara S. Barton‐Maclaren(AstraZeneca (United Kingdom)), Candice Johnson(LeadScope (United States)), Robert A. Jolly(Eli Lilly (United States)), David Jones, Ray Kemper(Sanofi (Germany)), Michelle Kenyon(Pfizer (United States)), Naomi L. Kruhlak(Center for Drug Evaluation and Research), Sunil Kulkarni(Health Canada), Klaus Kümmerer(Leuphana University of Lüneburg), Penny Leavitt(Bristol-Myers Squibb (Germany)), Scott A. Masten(National Institute of Environmental Health Sciences), Scott A. Miller(National Institute of Environmental Health Sciences), Chandrika Moudgal(Nestlé (Switzerland)), Wolfgang Muster(Roche (Switzerland)), Alexandre Tadeu Paulino(Nestlé (Switzerland)), Elena Lo Piparo(Nestlé (Switzerland)), Mark W. Powley(United States Military Academy), Donald P. Quigley(LeadScope (United States)), M. Vijayaray Reddy(United States Military Academy), Andrea-Nicole Richarz(Joint Research Centre), Benoı̂t Schilter(Nestlé (Switzerland)), Ronald D. Snyder(ABS Consulting (United States)), Lidiya Stavitskaya(Center for Drug Evaluation and Research), Reinhard Stidl(AstraZeneca (United Kingdom)), David T. Szabo(PPG Industries (United States)), Andrew Teasdale(AstraZeneca (United Kingdom)), Raymond R. Tice(Hillsborough Community College), Alejandra Trejo‐Martin(Nestlé (Switzerland)), Anna Vuorinen(DSM (Switzerland)), B. Wall(Nestlé (Switzerland)), Pete Watts(Bibra International), Angela White(GlaxoSmithKline (United Kingdom)), Joerg Wichard(ABS Consulting (United States)), Kristine L. Witt(Leuphana University of Lüneburg), Adam Woolley(Leuphana University of Lüneburg), David Woolley(National One Call (United Kingdom)), Craig Zwickl(Health Canada), Glenn J. Myatt(LeadScope (United States))
Regulatory Toxicology and Pharmacology
June 10, 2019
Cited by 79Open Access
Full Text

Abstract

In silico toxicology (IST) approaches to rapidly assess chemical hazard, and usage of such methods is increasing in all applications but especially for regulatory submissions, such as for assessing chemicals under REACH as well as the ICH M7 guideline for drug impurities. There are a number of obstacles to performing an IST assessment, including uncertainty in how such an assessment and associated expert review should be performed or what is fit for purpose, as well as a lack of confidence that the results will be accepted by colleagues, collaborators and regulatory authorities. To address this, a project to develop a series of IST protocols for different hazard endpoints has been initiated and this paper describes the genetic toxicity in silico (GIST) protocol. The protocol outlines a hazard assessment framework including key effects/mechanisms and their relationships to endpoints such as gene mutation and clastogenicity. IST models and data are reviewed that support the assessment of these effects/mechanisms along with defined approaches for combining the information and evaluating the confidence in the assessment. This protocol has been developed through a consortium of toxicologists, computational scientists, and regulatory scientists across several industries to support the implementation and acceptance of in silico approaches.


Related Papers

No related papers found

Powered by citation graph analysis